Lupus

New research at ACR 2025 highlights the link between cognitive impairment and disease activity in SLE.

A recent exploratory analysis reveals significant kidney B-cell depletion by the recently approved drug.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and colorectal cancer screening updates, in this week's essential news roundup.

View slated expert interviews and 6 clinical RA, PsA, and lupus trials to watch at ACR 2025.

The decision is supported by positive results from the phase 2 NOBILITY and phase 3 REGENCY studies.

However, a notable higher rate of treatment-related adverse events warrants caution.

Upadacitinib reduced glucocorticoid doses and improved disease activity over 104 weeks.

Nearly a third of patients with lupus in APPEAL reported falls, with disease activity, depressive symptoms, and medication use among key risk factors.

Santerus AG is preparing to initiate clinical trials of its blood purification technology in a variety of indications.

This session at the DERM 2025 conference highlights several clinical pearls in dermatology and was presented by rheumatologist Karim Ladak, MD.

New phase 3 trial data reveals Dapirolizumab pegol significantly reduces disease activity and fatigue in systemic lupus erythematosus patients, promising improved treatment outcomes.

This FDA News Month in Review provides a round-up of regulatory decisions from June 2025.

An audio recap of the top 5 stories in healthcare news from the week of 06/16-06/22

Stay updated with the latest healthcare breakthroughs, including new phase 2/3 clinical trial data and an FDA approval, in this week's essential news roundup.

With the approval, children ≥ 5 years of age with active lupus nephritis will have a first-of-its-kind treatment option for at-home administration.

Recent studies reveal belimumab's effectiveness in treating lupus nephritis, showing significant renal response and improved patient outcomes in real-world settings.

Sayna Norouzi, MD, discusses results from a pair of trials examining QoL in patients with lupus from ERA 2025.

New analysis reveals obinutuzumab's potential to improve kidney inflammation and biomarkers in lupus nephritis.

A recent study reveals significant variations in biologic use among pregnant patients with autoimmune diseases, highlighting the need for tailored risk-benefit assessments.

EMD Serono previously announced that its CLE cohort had met its primary endpoint while its SLE cohort failed to follow suit.

A recent meta-analysis confirms belimumab's superior efficacy over placebo in treating systemic lupus erythematosus, potentially informing clinical management strategies.

The filing acceptance is based on positive data from the phase 3 REGENCY study. A decision on the approval is expected by October 2025.

Furie discussed topline data from the REGENCY trial and key secondary endpoints.